Key statistics dashboard for NewAmsterdam Pharma Company N.V. (NAMS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Stock Data
| Price | $21.18 |
| Market Cap | $2.5B |
| Enterprise Value | $2.05B |
| Beta | 0.13 |
| Exchange | NASDAQ |
| Country | NL |
Valuation Multiples
| P/E Ratio | -9.71 |
| Price / Book | 4.13 |
| P/S | 347.38 |
| EV/EBITDA | -8.05 |
| EV/Sales | 288.16 |
| EV/FCF | -14.28 |
| P/FCF | -17.21 |
| Earnings Yield | -9.93% |
| FCF Yield | -5.80% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 92.15% |
| EBIT Margin | -3583.09% |
| EBITDA Margin | -3579.24% |
| Operating Margin | -3432.20% |
| Net Margin | -3644.21% |
| Return on Equity | -38.33% |
| Return on Assets | -36.84% |
| Return on Invested Capital | -38.70% |
| Return on Capital Employed | -38.70% |
Financial Health
| Current Ratio | 9.03 |
| Quick Ratio | 9.03 |
| Cash Ratio | 5.81 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.01% |
| Net Debt / EBITDA | 1.66 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.06 |
| Book Value per share | 5.12 |
| Cash per share | 5.14 |
| FCF per share | -1.16 |
| Tangible Book Value per share | 5.12 |
| Dividend per share | 0.00 |
Related companies: ACLX · AKRO · CGON · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks